1WHO | Global Action Plan for the Prevention and Control of NCDs 2013-2020 [Internet]. [cited 2018 Dec 9].

2Natarajan P, Jaiswal S, Kathiresan S (2018) Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis. Circ Genomic Precis Med11:e001926.

3Virchow R (1858) Cellular Pathology. London: John Churchill.

4Libby P (2012) History of Discovery: Inflammation in Atherosclerosis. Arterioscler Thromb Vasc Biol 32:2045–2051.

5Libby P (1990) Inflammatory and immune mechanisms in atherogenesis. Vol. Vol 21. New York: Raven Press; 79–89.

6Pant S, Deshmukh A, Gurumurthy GS, Pothineni NV, Watts TE, Romeo F, et al. (2014) Inflammation and atherosclerosis—revisited.J Cardiovasc Pharmacol Ther. 19:170-178.

7Kavurma MM, Rayner KJ, Karunakaran D (2017) The walking dead: macrophage inflammation and death in atherosclerosis. CurrOpinLipidol. 28: 91-98.

8Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. (2012) Third universal definition of myocardial infarction. J Am CollCardiol 60: 1581–1598.

9Yamashita H, Shimada K, Seki E, Mokuno H, Daida H (2003) Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 91:133–136.

10Tabrez S, Ali M, Jabir NR, Firoz CK, Ashraf GM, Hindawi S, et al. (2017) A putative association of interleukin-10 promoter polymorphisms with cardiovascular disease. IUBMB Life 69: 522–527.

11Chalikias GK, Tziakas DN, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, et al. (2007) Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol 117: 333–339.

12Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, et al. (2002) Increased plasma concentrations of interleukin- 18 in acute coronary syndromes. Heart 88:467-469.

13Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101: 1372–1378.

14Ridker PM, Rifai N, Stampfer MJ, Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767–1772.

15Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, et al. (2017) Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib -Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 6.

16Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 101: 2149–2153.

17Heinisch RH, Zanetti CR, Comin F, Fernandes JL, Ramires JA, Serrano CV (2005) Serial Changes in Plasma Levels of Cytokines in Patients with Coronary Artery Disease. Vasc Health Risk Manag 1: 245–250.

18Widen C, Holmer H, Coleman M, Tudor M, Ohlsson O, Sättlin S, et al. (2016) Systemic inflammatory impact of periodontitis on acute coronary syndrome. J Clin Periodontol 43: 713–719.

19Liu K, Tang Q, Zhu X, Yang X (2017) IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction. Clin Chim Acta Int J Clin Chem 468: 140–144.

20Wang K, Chen L, Liu L, Cui Y, Zhang X, Jiang J (2018) The effects of atorvastatin on IL-6, CRP, blood lipid and myocardial protection of interventional therapy in patients with acute myocardial infarction. Minerva Med.